TABLE 1.
Patient Characteristics
| Trial | All | Bevacizumab | Enzastaurin |
|---|---|---|---|
| N | 24 | 13 | 11 |
| Age (years) | 52 | 51 | 57 |
| Progression-free survival (days) | 323 | 377 | 142 |
| Overall survival (days) | 552 | 619 | 422 |
| Male | 15 | 6 | 9 |
| Female | 9 | 7 | 2 |
| GTR | 11 | 7 | 4 |
| STR | 11 | 5 | 6 |
| Biopsy | 2 | 1 | 1 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.